September 2026– date –
-
FDA: Non-animal testing standard roadmap and 2030 timeline
Vertex AI Search USA Overview The FDA announced plans to remove animal testing references from drug regulations, clarifying that companies can seek drug approval without animal data. This pivotal shift encourages the use of alternative m... -
Sotyktu: Bristol Myers Squibb’s first oral TYK2 inhibitor FDA specs
MarketBeat USA Overview Bristol Myers Squibb (BMS) announced FDA approval on March 6, 2026, for Sotyktu® (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of active psoriatic arthritis in adults. ... -
Elunetirom: Phase 2 AMPLIFY-BD trial results for bipolar depression
Pharmacally International Overview Elunetirom demonstrated favorable results in the Phase 2 AMPLIFY-BD open-label trial for bipolar depression, significantly reducing depressive symptoms and improving patient function. In 21 adults with ... -
LUNAR 2.0: Arcturus Therapeutics mRNA expression roadmap
Morningstar USA Overview Arcturus Therapeutics announced interim Phase 2 results for ARCT-810 in OTC Deficiency and unveiled its next-generation mRNA delivery platform, LUNAR 2.0™. ARCT-810 demonstrated a favorable safety profile and pro... -
mRNA Vaccine LNP: South Korea’s 2026 organ targeting specs
Vertex AI Search South Korea Overview In South Korea, new lipid nanoparticle (LNP) strategies for mRNA vaccines are being developed, including Selective Organ Targeting (SORT) to lung, spleen, and lymph nodes, and ligand conjugation to L... -
AI drug discovery: 80-90% Phase I success rate explained
World Health Expo International Overview AI-identified drug candidates have demonstrated an impressive 80-90% success rate in Phase I clinical trials, significantly surpassing the historical industry average. This breakthrough is driven ... -
Orforglipron: Eli Lilly oral GLP-1 vs injectable efficacy
Apps Script USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, has shown potent weight loss and glycemic control effects in early clinical trials comparable to injectable GLP-1 drugs for type 2 diabetes a... -
Oral GLP-1 drugs: 2026 clinical trial bioavailability specs
Vertex AI Search (grounding-api-redirect) USA Overview New oral GLP-1 medications in clinical trials have significantly improved bioavailability through the use of novel absorption enhancers, overcoming traditional degradation challenges... -
EV Battery Restoration: Chemical bath SEI removal method explained
Good News Network USA Overview Scientists have developed a novel chemical bath method to restore degraded EV batteries without disassembly. This technique removes the solid electrolyte interphase (SEI) layer, a primary cause of lithium-i... -
CATL: All-solid-state battery production timeline for 2027
Pandaily China Overview CATL aims for small-batch production of all-solid-state batteries by 2027, though current technology remains at TRL-4 (laboratory principle verification). Sulfide solid electrolytes, being moisture-sensitive and p...
